Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49


Threonine Tyrosine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy.

Zheng L, Chen Z, Kawakami M, Chen Y, Roszik J, Mustachio LM, Kurie JM, Villalobos P, Lu W, Behren C, Mino B, Solis LM, Silvester J, Thu KL, Cescon DW, Rodriguez-Canales J, Wistuba II, Mak TW, Liu X, Dmitrovsky E.

Mol Cancer Ther. 2019 Jul 29. pii: molcanther.0864.2018. doi: 10.1158/1535-7163.MCT-18-0864. [Epub ahead of print]


Benchmarking to the Gold Standard: Hyaluronan-Oxime Hydrogels Recapitulate Xenograft Models with In Vitro Breast Cancer Spheroid Culture.

Baker AEG, Bahlmann LC, Tam RY, Liu JC, Ganesh AN, Mitrousis N, Marcellus R, Spears M, Bartlett JMS, Cescon DW, Bader GD, Shoichet MS.

Adv Mater. 2019 Sep;31(36):e1901166. doi: 10.1002/adma.201901166. Epub 2019 Jul 19.


Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial.

Veitch ZW, Cescon DW, Denny T, Yonemoto LM, Fletcher G, Brokx R, Sampson P, Li SW, Pugh TJ, Bruce J, Bray MR, Slamon DJ, Mak TW, Wainberg ZA, Bedard PL.

Br J Cancer. 2019 Aug;121(4):318-324. doi: 10.1038/s41416-019-0517-3. Epub 2019 Jul 15.


Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts.

Mer AS, Ba-Alawi W, Smirnov P, Wang YX, Brew B, Ortmann J, Tsao MS, Cescon DW, Goldenberg A, Haibe-Kains B.

Cancer Res. 2019 Sep 1;79(17):4539-4550. doi: 10.1158/0008-5472.CAN-19-0349. Epub 2019 May 29.


Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1.

Roux C, Jafari SM, Shinde R, Duncan G, Cescon DW, Silvester J, Chu MF, Hodgson K, Berger T, Wakeham A, Palomero L, Garcia-Valero M, Pujana MA, Mak TW, McGaha TL, Cappello P, Gorrini C.

Proc Natl Acad Sci U S A. 2019 Feb 15. pii: 201819473. doi: 10.1073/pnas.1819473116. [Epub ahead of print]


AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer.

Kubli SP, Bassi C, Roux C, Wakeham A, Göbl C, Zhou W, Jafari SM, Snow B, Jones L, Palomero L, Thu KL, Cassetta L, Soong D, Berger T, Ramachandran P, Baniasadi SP, Duncan G, Lindzen M, Yarden Y, Herranz C, Lazaro C, Chu MF, Haight J, Tinto P, Silvester J, Cescon DW, Petit A, Pettersson S, Pollard JW, Mak TW, Pujana MA, Cappello P, Gorrini C.

Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3604-3613. doi: 10.1073/pnas.1815126116. Epub 2019 Feb 7.


Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.

Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J.

Ann Oncol. 2019 Mar 1;30(3):397-404. doi: 10.1093/annonc/mdy517.


Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.

Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, Liu MC, Iwata H, Ryvo L, Wimberger P, Rugo HS, Tan AR, Jia L, Ding Y, Karantza V, Schmid P.

Ann Oncol. 2019 Mar 1;30(3):405-411. doi: 10.1093/annonc/mdy518.


The Antiarrhythmic Drug, Dronedarone, Demonstrates Cytotoxic Effects in Breast Cancer Independent of Thyroid Hormone Receptor Alpha 1 (THRα1) Antagonism.

Elliott MJ, Jerzak KJ, Cockburn JG, Safikhani Z, Gwynne WD, Hassell JA, Bane A, Silvester J, Thu KL, Haibe-Kains B, Mak TW, Cescon DW.

Sci Rep. 2018 Nov 8;8(1):16562. doi: 10.1038/s41598-018-34348-0.


Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition.

Kawakami M, Mustachio LM, Zheng L, Chen Y, Rodriguez-Canales J, Mino B, Kurie JM, Roszik J, Villalobos PA, Thu KL, Silvester J, Cescon DW, Wistuba II, Mak TW, Liu X, Dmitrovsky E.

Proc Natl Acad Sci U S A. 2018 Nov 13;115(46):E10810-E10811. doi: 10.1073/pnas.1813967115. Epub 2018 Oct 30. No abstract available.


MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis.

Tu WB, Shiah YJ, Lourenco C, Mullen PJ, Dingar D, Redel C, Tamachi A, Ba-Alawi W, Aman A, Al-Awar R, Cescon DW, Haibe-Kains B, Arrowsmith CH, Raught B, Boutros PC, Penn LZ.

Cancer Cell. 2018 Oct 8;34(4):579-595.e8. doi: 10.1016/j.ccell.2018.09.001.


Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy.

Algorashi I, Goldvaser H, Ribnikar D, Cescon DW, Amir E.

Cancer Treat Rev. 2018 Nov;70:138-143. doi: 10.1016/j.ctrv.2018.08.009. Epub 2018 Aug 24. Review.


Targeting the cell cycle in breast cancer: towards the next phase.

Thu KL, Soria-Bretones I, Mak TW, Cescon DW.

Cell Cycle. 2018;17(15):1871-1885. doi: 10.1080/15384101.2018.1502567. Epub 2018 Sep 11. Review.


Gene Expression Analyses in Breast Cancer: Sample Matters.

Haibe-Kains B, Cescon DW.

JNCI Cancer Spectr. 2018 May 22;2(2):pky019. doi: 10.1093/jncics/pky019. eCollection 2018 Apr. No abstract available.


Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers.

Kawakami M, Mustachio LM, Zheng L, Chen Y, Rodriguez-Canales J, Mino B, Kurie JM, Roszik J, Villalobos PA, Thu KL, Silvester J, Cescon DW, Wistuba II, Mak TW, Liu X, Dmitrovsky E.

Proc Natl Acad Sci U S A. 2018 Feb 20;115(8):1913-1918. doi: 10.1073/pnas.1719760115. Epub 2018 Feb 6.


Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization.

Siddiqui-Jain A, Hoj JP, Cescon DW, Hansen MD.

Bioorg Med Chem Lett. 2018 Mar 1;28(5):934-941. doi: 10.1016/j.bmcl.2018.01.053. Epub 2018 Feb 9.


Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis.

Goldvaser H, Majeed H, Ribnikar D, Šeruga B, Ocaña A, Cescon DW, Amir E.

Breast Cancer Res Treat. 2018 Jun;169(3):413-425. doi: 10.1007/s10549-018-4710-5. Epub 2018 Feb 8. Review.


Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer.

Thu KL, Silvester J, Elliott MJ, Ba-Alawi W, Duncan MH, Elia AC, Mer AS, Smirnov P, Safikhani Z, Haibe-Kains B, Mak TW, Cescon DW.

Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1570-E1577. doi: 10.1073/pnas.1719577115. Epub 2018 Jan 29.


Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.

Pezo RC, Chen TW, Berman HK, Mulligan AM, Razak AA, Siu LL, Cescon DW, Amir E, Elser C, Warr DG, Sridhar SS, Yu C, Wang L, Stockley TL, Kamel-Reid S, Bedard PL.

Breast Cancer Res Treat. 2018 Feb;168(1):159-168. doi: 10.1007/s10549-017-4580-2. Epub 2017 Nov 24.


Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis.

Goldvaser H, Barnes TA, Šeruga B, Cescon DW, Ocaña A, Ribnikar D, Amir E.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx141. Review.


Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials.

Natori A, Ethier JL, Amir E, Cescon DW.

Eur J Cancer. 2017 May;77:40-47. doi: 10.1016/j.ejca.2017.02.024. Epub 2017 Mar 27. Review.


BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial.

Liu G, Cuffe S, Liang S, Azad AK, Cheng L, Brhane Y, Qiu X, Cescon DW, Bruce J, Chen Z, Cheng D, Patel D, Tse BC, Laurie SA, Goss G, Leighl NB, Hung R, Bradbury PA, Seymour L, Shepherd FA, Tsao MS, Chen BE, Xu W, Reisman DN.

Clin Cancer Res. 2017 May 15;23(10):2460-2470. doi: 10.1158/1078-0432.CCR-16-1640. Epub 2016 Nov 8.


DNA replication stress: a source of APOBEC3B expression in breast cancer.

Cescon DW, Haibe-Kains B.

Genome Biol. 2016 Sep 30;17(1):202. Review.


Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer.

Bailey SD, Desai K, Kron KJ, Mazrooei P, Sinnott-Armstrong NA, Treloar AE, Dowar M, Thu KL, Cescon DW, Silvester J, Yang SY, Wu X, Pezo RC, Haibe-Kains B, Mak TW, Bedard PL, Pugh TJ, Sallari RC, Lupien M.

Nat Genet. 2016 Oct;48(10):1260-6. doi: 10.1038/ng.3650. Epub 2016 Aug 29.


Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.

Inoue S, Li WY, Tseng A, Beerman I, Elia AJ, Bendall SC, Lemonnier F, Kron KJ, Cescon DW, Hao Z, Lind EF, Takayama N, Planello AC, Shen SY, Shih AH, Larsen DM, Li Q, Snow BE, Wakeham A, Haight J, Gorrini C, Bassi C, Thu KL, Murakami K, Elford AR, Ueda T, Straley K, Yen KE, Melino G, Cimmino L, Aifantis I, Levine RL, De Carvalho DD, Lupien M, Rossi DJ, Nolan GP, Cairns RA, Mak TW.

Cancer Cell. 2016 Aug 8;30(2):337-348. doi: 10.1016/j.ccell.2016.05.018. Epub 2016 Jul 14.


A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041).

Chiu JW, Hotte SJ, Kollmannsberger CK, Renouf DJ, Cescon DW, Hedley D, Chow S, Moscow J, Chen Z, Perry M, Diaz-Padilla I, Tan D, Hirte H, McWhirter E, Chen H, Siu LL, Bedard PL.

Invest New Drugs. 2016 Feb;34(1):104-11. doi: 10.1007/s10637-015-0313-8. Epub 2015 Dec 19.


Idh1 protects murine hepatocytes from endotoxin-induced oxidative stress by regulating the intracellular NADP(+)/NADPH ratio.

Itsumi M, Inoue S, Elia AJ, Murakami K, Sasaki M, Lind EF, Brenner D, Harris IS, Chio II, Afzal S, Cairns RA, Cescon DW, Elford AR, Ye J, Lang PA, Li WY, Wakeham A, Duncan GS, Haight J, You-Ten A, Snow B, Yamamoto K, Ohashi PS, Mak TW.

Cell Death Differ. 2015 Nov;22(11):1837-45. doi: 10.1038/cdd.2015.38. Epub 2015 Apr 17.


NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma.

Cescon DW, She D, Sakashita S, Zhu CQ, Pintilie M, Shepherd FA, Tsao MS.

Clin Cancer Res. 2015 Jun 1;21(11):2499-505. doi: 10.1158/1078-0432.CCR-14-2206. Epub 2015 Mar 4.


APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation.

Cescon DW, Haibe-Kains B, Mak TW.

Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):2841-6. doi: 10.1073/pnas.1424869112. Epub 2015 Feb 17.


Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression.

Harris IS, Treloar AE, Inoue S, Sasaki M, Gorrini C, Lee KC, Yung KY, Brenner D, Knobbe-Thomsen CB, Cox MA, Elia A, Berger T, Cescon DW, Adeoye A, Brüstle A, Molyneux SD, Mason JM, Li WY, Yamamoto K, Wakeham A, Berman HK, Khokha R, Done SJ, Kavanagh TJ, Lam CW, Mak TW.

Cancer Cell. 2015 Feb 9;27(2):211-22. doi: 10.1016/j.ccell.2014.11.019. Epub 2015 Jan 22. Erratum in: Cancer Cell. 2015 Feb 9;27(2):314.


Breaking up is hard to do: PI3K isoforms on the rebound.

Cescon DW, Gorrini C, Mak TW.

Cancer Cell. 2015 Jan 12;27(1):5-7. doi: 10.1016/j.ccell.2014.12.003.


PIK3CA genotype and treatment decisions in human epidermal growth factor receptor 2-positive breast cancer.

Cescon DW, Bedard PL.

J Clin Oncol. 2015 Apr 20;33(12):1318-21. doi: 10.1200/JCO.2014.59.3160. Epub 2015 Jan 5. No abstract available.


Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent.

Mason JM, Lin DC, Wei X, Che Y, Yao Y, Kiarash R, Cescon DW, Fletcher GC, Awrey DE, Bray MR, Pan G, Mak TW.

Cancer Cell. 2014 Aug 11;26(2):163-76. doi: 10.1016/j.ccr.2014.05.006. Epub 2014 Jul 17.


Extended adjuvant tamoxifen for early breast cancer: a meta-analysis.

Al-Mubarak M, Tibau A, Templeton AJ, Cescon DW, Ocana A, Seruga B, Amir E.

PLoS One. 2014 Feb 20;9(2):e88238. doi: 10.1371/journal.pone.0088238. eCollection 2014.


Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway.

Gorrini C, Gang BP, Bassi C, Wakeham A, Baniasadi SP, Hao Z, Li WY, Cescon DW, Li YT, Molyneux S, Penrod N, Lupien M, Schmidt EE, Stambolic V, Gauthier ML, Mak TW.

Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4472-7. doi: 10.1073/pnas.1324136111. Epub 2014 Feb 24.


BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival.

Gorrini C, Baniasadi PS, Harris IS, Silvester J, Inoue S, Snow B, Joshi PA, Wakeham A, Molyneux SD, Martin B, Bouwman P, Cescon DW, Elia AJ, Winterton-Perks Z, Cruickshank J, Brenner D, Tseng A, Musgrave M, Berman HK, Khokha R, Jonkers J, Mak TW, Gauthier ML.

J Exp Med. 2013 Jul 29;210(8):1529-44. doi: 10.1084/jem.20121337. Epub 2013 Jul 15.


Feasibility of a randomized controlled trial of vitamin D vs. placebo in women with recently diagnosed breast cancer.

Cescon DW, Ganz PA, Beddows S, Ennis M, Mills BK, Goodwin PJ.

Breast Cancer Res Treat. 2012 Jul;134(2):759-67. doi: 10.1007/s10549-012-2120-7. Epub 2012 Jun 16.


Pharmacogenetic and germline prognostic markers of lung cancer.

Horgan AM, Yang B, Azad AK, Amir E, John T, Cescon DW, Wheatley-Price P, Hung RJ, Shepherd FA, Liu G.

J Thorac Oncol. 2011 Feb;6(2):296-304. doi: 10.1097/JTO.0b013e3181ffe909.


Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer.

Seruga B, Hertz PC, Wang L, Booth CM, Cescon DW, Krzyzanowska M, Tannock IF.

Ann Oncol. 2010 Jul;21(7):1411-8. doi: 10.1093/annonc/mdp552. Epub 2009 Nov 30.


Presentation of nonfinal results of randomized controlled trials at major oncology meetings.

Booth CM, Le Maître A, Ding K, Farn K, Fralick M, Phillips C, Cescon DW, Meyer RM.

J Clin Oncol. 2009 Aug 20;27(24):3938-44. doi: 10.1200/JCO.2008.18.8771. Epub 2009 Jul 20.


p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis.

Cescon DW, Bradbury PA, Asomaning K, Hopkins J, Zhai R, Zhou W, Wang Z, Kulke M, Su L, Ma C, Xu W, Marshall AL, Heist RS, Wain JC, Lynch TJ Jr, Christiani DC, Liu G.

Clin Cancer Res. 2009 May 1;15(9):3103-9. doi: 10.1158/1078-0432.CCR-08-3120. Epub 2009 Apr 21.


p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinoma.

Liu G, Cescon DW, Zhai R, Zhou W, Kulke MH, Ma C, Xu W, Su L, Asomaning K, Heist RS, Wain JC, Lynch TJ, Christiani DC.

Dis Esophagus. 2010 Jan;23(1):36-9. doi: 10.1111/j.1442-2050.2009.00960.x. Epub 2009 Mar 17.


Discoloration of skin and urine after treatment with hydroxocobalamin for cyanide poisoning.

Cescon DW, Juurlink DN.

CMAJ. 2009 Jan 20;180(2):251. doi: 10.1503/cmaj.080727. No abstract available.


Evolution of the randomized controlled trial in oncology over three decades.

Booth CM, Cescon DW, Wang L, Tannock IF, Krzyzanowska MK.

J Clin Oncol. 2008 Nov 20;26(33):5458-64. doi: 10.1200/JCO.2008.16.5456. Epub 2008 Oct 27.


Bowel loops and eyelid droops.

Spiegelman J, Cescon DW, Friedman Y, Mazza BV, Austin JW, Rachlis A, Murray BJ.

CMAJ. 2008 Oct 21;179(9):927-9. doi: 10.1503/cmaj.080651.


Barcoded medication administration: a last line of defense.

Cescon DW, Etchells E.

JAMA. 2008 May 14;299(18):2200-2. doi: 10.1001/jama.299.18.2200. No abstract available.


Invasive pulmonary aspergillosis associated with marijuana use in a man with colorectal cancer.

Cescon DW, Page AV, Richardson S, Moore MJ, Boerner S, Gold WL.

J Clin Oncol. 2008 May 1;26(13):2214-5. doi: 10.1200/JCO.2007.15.2777. No abstract available. Erratum in: J Clin Oncol. 2008 Aug 20;26(24):4053.


Genetic polymorphisms and head and neck cancer outcomes: a review.

Hopkins J, Cescon DW, Tse D, Bradbury P, Xu W, Ma C, Wheatley-Price P, Waldron J, Goldstein D, Meyer F, Bairati I, Liu G.

Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):490-9. doi: 10.1158/1055-9965.EPI-07-2714. Review.


Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.

Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, Walmsley SL, Mazzulli T, Avendano M, Derkach P, Ephtimios IE, Kitai I, Mederski BD, Shadowitz SB, Gold WL, Hawryluck LA, Rea E, Chenkin JS, Cescon DW, Poutanen SM, Detsky AS.

JAMA. 2003 Jun 4;289(21):2801-9. Epub 2003 May 6. Erratum in: JAMA. 2003 Jul 16;290(3):334.


Supplemental Content

Loading ...
Support Center